central and peripheral glp-1 systems independently suppress eating Potential mechanisms of weight loss caused by the effects of GLP‐1 Glucagon-Like Peptide-1: New Regulator in

CHNG OXY HA, CHNG VIM MNH To xon ni ting vi hm lng cht chng oxy ha cao, c bit l phycocyanin, mt sc t mu xanh to nn mu sc c trng ca to

2 Other examples of GLP-1 agonists available in Canada include dulaglutide (Trulicity), liraglutide (Saxenda), lixisenatide (Adlyxine), and tirzepatide (Mounjaro)

These scans help establish a baseline and support informed decision-making throughout your health and wellness journey

Early real-world GLP-1 data shows: - 6070% reductions in progression to diabetes - Significant decreases in cardiovascular events - Reduced need for costly downstream care such as hospitalizations and dialysis For the first time, a single class of medications has the potential to reduce spending across multiple multi-billion-dollar disease categories

Distribution of GLP-1 fibers in the spinal cord We correlated the distribution of GLP-1R-IR neuronal elements with the GLP-1 innervation of the spinal cord that originates primarily, if not exclusively, from lower brainstem neurons 20